IL4 and pulmonary fibrosis: Despite the fact that overwhelming evidence exists regarding the role of type 2 immunity in lung fibrosis, these findings should be contrasted with the disappointing results of therapeutic trials of IL-13 and dual IL-4/IL-13 inhibition in IPF, which both failed to meet their therapeutic endpoints (188, 189).